Clinical trial · Interventional
Monoclonal Antibody Vaccine Therapy in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer
Phase I Trial of the Monoclonal Anti-Idiotype Antibody ACA125 in Patients With Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
NCT00058435CI-TRIAL-00010625completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Vaccines made from monoclonal antibodies combined with tumor cells may make the body build an immune response to kill tumor cells. PURPOSE: Randomized phase I trial to study the effectiveness of vaccine therapy in treating patients who have ovarian epithelial, fallopian tube, or peritoneal cancer.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Fallopian Tube Cancer | Malignant Fallopian Tube Neoplasm | ALIAS | 0.90 |
| Ovarian Cancer | Malignant Ovarian Neoplasm | CURATED_EXACT | 0.92 |
| Primary Peritoneal Cavity Cancer | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| abagovomab | Biological | — | UNRESOLVED |
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Histologically confirmed ovarian epithelial, fallopian tube, or peritoneal cancer * Stage II-IV * Initially treated with surgery and at least 1 platinum-based chemotherapy regimen * Must have relapsed after initial treatment and completed chemotherapy for recurrent disease * Asymptomatic residual measurable disease on CT scan and/or an elevated CA 125 allowed * Complete clinical remission allowed, defined by the following criteria: * CA 125 no greater than 35 IU/mL * No objective evidence of disease by CT scan * Normal physical examination PATIENT CHARACTERISTICS: Age * 18 and over Performance status * Karnofsky 70-100% Life expectancy * At least 3 months Hematopoietic * WBC at least 1,500/mm\^3 * Platelet count at least 100,000/mm\^3 * Hemoglobin at least 10 g/dL Hepatic * Bilirubin no greater than 2 times normal * ALT no greater than 2 times normal * Alkaline phosphatase no greater than 2 times normal Renal * Creatinine no greater than 1.5 times normal Other * Not pregnant or nursing * No potential for child bearing * Human antimurine antibody negative * HIV negative * No other malignancy within the past 5 years except nonmelanoma skin cancer or carcinoma in situ of the cervix * No active infection * No known autoimmune disease (e.g., rheumatoid arthritis or ulcerative colitis) * No known immune deficiency (e.g., hypogammaglobulinemia) * No known allergy to murine proteins PRIOR CONCURRENT THERAPY: Biologic therapy * At least 6 weeks since prior interferon * At least 6 weeks since prior immunotherapy or biological response modifiers * No prior anticancer vaccine Chemotherapy * See Disease Characteristics * At least 3 weeks since prior cytotoxic or investigational chemotherapy Endocrine therapy * No concurrent steroids Radiotherapy * At least 4 weeks since prior radiotherapy Surgery * See Disease Characteristics Other * At least 1 week since prior antibiotics * No concurrent cyclosporine * No other concurrent immunosuppressive therapy
References
Publications (0)
Data not yet available
No reference posted for this study.